Vaccinia Capping Enzyme, GMP Grade (GMP-VCS-VE101)
|Product Description||The 7-methylguanosine cap structure(m7Gppp, Cap0) is a specific feature in eukaryotic mRNA, which is required for mRNA stability, splicing, nuclear export, effective translation, and mRNA decay. Vaccinia Capping Enzyme, a heterodimer of D1(844 aa) and D12(287 aa) subunits, adding the Cap0 structure to the 5' end of the RNA. The D1 subunit comprises an N-terminal RNA triphosphatase(TPase), a guanylyltransferase(GTase), and a C-terminal guanine-N7-methyltransferase(MTase). The D12 subunit binds and stimulates the MTase.
mRNA Cap 2'-O-Methyltransferase (Kactus #GMP-MEH-VE101) is required to generate Cap 1 structure that reduces cellular innate immune response when the RNA is used in vivo.
Expressed in an E.coli strain carries the genes of the Vaccinia virus Capping Enzyme.
|Product Category||GMP Enzyme|
In Vitro Synthesis(IVT)
Labeling 5' end of mRNA
|Unit Definition||One unit is defined as the amount of enzyme required to incorporate 10 pmol of (α32P) GTP into an 80 nt transcript in 1 hour at 37°C.|
Manufactured to the GMP guidelines Antibiotic-free and animal-free production Suitable for manufacturing of mRNA therapeutics and vaccines
|QC Standard||Activity: >=12.7 kU/ml
Residual Endonuclease: Negative
Residual Exonuclease: Negative
Residual RNase: Negative
Residual Protease: Negative
Endotoxin: <=10 EU/ml
Residual Host Cell DNA: <=100 pg/MG
Residual Host Protein: <=50 ng/MG
Bioburden: <=1 CFU/10 ml
|Shipping||Shipped with blue ice|
|Stability And Storage||-20°C for 12 months. Avoid repeated freeze-thaw cycles.|